{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Neuronal Signal Pathway > Vortioxetine HydrobromideCAS：960203-27-4
Molecular Formula：C18H23BrN2S
Molecular Weight：379.36
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 960203-27-4 |
| Name | Vortioxetine Hydrobromide |
| Molecular Formula | C18H23BrN2S |
| Molecular Weight | 379.36 |
| Solubility | Soluble in DMSO(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00003305 |
| SMILES | CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Br |
| InChIKey | VNGRUFUIHGGOOM-UHFFFAOYSA-N |
| InChI | InChI=1S/C18H22N2S.BrH/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20;/h3-8，13，19H，9-12H2，1-2H3;1H |
| PubChem CID | 56843850 |
| Target Point | 5-HT Receptor;Serotonin Transporter |
| Passage | Neuronal Signaling；GPCR & G Protein |
| Background | It is an inhibitor of the 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and the serotonin transporter (SERT). |
| Biological Activity | Vortioxetine Hydrobromide 是 5-HT1A，5-HT1B，5-HT3A，5-HT7 受体 和5-羟色胺转运体 (SERT) 的抑制剂，其Ki值分别为 15 nM，33 nM，3.7 nM，19 nM 和 1.6 nM。[1] |
| Data Literature Source | [1]. Bang-Andersen B，et al. Discovery of 1-[2-(2，4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. [2]. Guilloux JP，et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 Oct;73:147-59. [3]. Theunissen EL，et al. A randomized trial on the acute and steady-state effects of a new antidepressant，vortioxetine (Lu AA21004)，on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93(6):493-501. [4]. Rothschild AJ，et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized，double-blind，placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66. [5]. M rk A，et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75. |
| Unit | Bottle |
| Specification | 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
